Login to Your Account



ASCO 2012 Roundup


Tuesday, June 5, 2012

• Cyclacel Pharmaceuticals Inc., of Berkeley Heights, N.J., provided new data from a Phase I trial of two product candidates, sapacitabine, a nucleoside analogue, and seliciclib, a CDK inhibitor, as an orally administered sequential treatment regimen in heavily pretreated patients with advanced solid tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription